Tumefactive demyelination presenting during bevacizumab treatment

Claire M Rice, David Rossiter, Janev Fehmi, James C Stevens, Shelley A Renowden, Nicki Cohen, Clare Bailey, Neil J Scolding

Research output: Contribution to journalArticle (Academic Journal)peer-review

5 Citations (Scopus)


We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

Original languageEnglish
JournalBMJ Case Reports
Publication statusPublished - 2015


Dive into the research topics of 'Tumefactive demyelination presenting during bevacizumab treatment'. Together they form a unique fingerprint.

Cite this